A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer.

doi:10.1038/nm.2713

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer.

Nature medicine - 18 Mar 2012

Ng King Pan, Hillmer Axel M, Chuah Charles T H, Juan Wen Chun, Ko Tun Kiat, Teo Audrey S M, Ariyaratne Pramila N, Takahashi Naoto, Sawada Kenichi, Fei Yao, Soh Sheila, Lee Wah Heng, Huang John W J, Allen John C, Woo Xing Yi, Nagarajan Niranjan, Kumar Vikrant, Thalamuthu Anbupalam, Poh Wan Ting, Ang Ai Leen, Mya Hae Tha, How Gee Fung, Yang Li Yi, Koh Liang Piu, Chowbay Balram, Chang Chia-Tien, Nadarajan Veera S, Chng Wee Joo, Than Hein, Lim Lay Cheng, Goh Yeow Tee, Zhang Shenli, Poh Dianne, Tan Patrick, Seet Ju-Ee, Ang Mei-Kim, Chau Noan-Minh, Ng Quan-Sing, Tan Daniel S W, Soda Manabu, Isobe Kazutoshi, Nöthen Markus M, Wong Tien Y, Shahab Atif, Ruan Xiaoan, Cacheux-Rataboul Valère, Sung Wing-Kin, Tan Eng Huat, Yatabe Yasushi, Mano Hiroyuki, Soo Ross A, Chin Tan Min, Lim Wan-Teck, Ruan Yijun, Ong S Tiong

Abstract excerpt

Tyrosine kinase inhibitors (TKIs) elicit high response rates among individuals with kinase-driven malignancies, including chronic myeloid leukemia (CML) and epidermal growth factor receptor-mutated non-small-cell lung cancer (EGFR NSCLC). However, the extent and duration of these responses are he...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Annexins

Share to Apoptosis Regulatory Proteins

Share to Bcl-2-Like Protein 11

Share to BH3 Interacting Domain Death Agonist Protein

Share to International Cooperation

Share to Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Share to RNA, Small Interfering

Share to Statistics, Nonparametric

Source

Open in PubMed

Identifiers

PMID: 22426421
DOI: 10.1038/nm.2713

Genes

EGFR
BCL2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-22426421-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer.PMID 22426421Read ↗

A systematic review and meta-analysis of individual patient data on the impact of the BIM deletion polymorphism on treatment outcomes in epidermal growth factor receptor mutant lung cancer.Semantic proximity Read ↗

Bcl-2-like protein 11 deletion polymorphism predicts survival in advanced non-small-cell lung cancer.Semantic proximity Read ↗

The Bim deletion polymorphism clinical profile and its relation with tyrosine kinase inhibitor resistance in Chinese patients with non-small cell lung cancer.Semantic proximity Read ↗

Prognostic Value of BIM Deletion in EGFR-Mutant NSCLC Patients Treated with EGFR-TKIs: A Meta-Analysis.Semantic proximity Read ↗

The BIM deletion polymorphism is a prognostic biomarker of EGFR-TKIs response in NSCLC: A systematic review and meta-analysis.Semantic proximity Read ↗

EGFR-TKI resistance due to BIM polymorphism can be circumvented in combination with HDAC inhibition.Semantic proximity Read ↗

Clinical significance of BIM deletion polymorphism in non-small-cell lung cancer with epidermal growth factor receptor mutation.Semantic proximity Read ↗

BIM Gene Polymorphism Lowers the Efficacy of EGFR-TKIs in Advanced Nonsmall Cell Lung Cancer With Sensitive EGFR Mutations: A Systematic Review and Meta-Analysis.Semantic proximity Read ↗

Clinical Implications of the BIM Deletion Polymorphism in Advanced Lung Adenocarcinoma Treated With Gefitinib.Semantic proximity Read ↗

EGFR Inhibitors Plus Bevacizumab are Superior Than EGFR Inhibitors Alone as First-Line Setting in Advanced NSCLC With EGFR Mutations and BIM Deletion Polymorphisms (BIM-CLICaP).Semantic proximity Read ↗

Efficacy of EGFR tyrosine kinase inhibitors in patients having EGFR-activating mutations with or without BIM polymorphisms.Semantic proximity Read ↗

Role of BIM Deletion Polymorphism and BIM Expression as Predictive Biomarkers to Maximize the Benefit of EGFR-TKI Treatment in EGFR-Positive NSCLC.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.